Becton, Dickinson and Company $BDX Shares Acquired by E. Ohman J or Asset Management AB

Posted by George Bondi on Oct 23rd, 2026

E. Ohman J or Asset Management AB increased its holdings in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 349.4% during the 3rd quarter, HoldingsChannel reports. The fund owned 45,863 shares of the medical instruments supplier’s stock after acquiring an additional 35,657 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Becton, Dickinson and Company were worth $8,209,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Becton, Dickinson and Company during the 2nd quarter worth approximately $3,721,533,000. State Street Corp boosted its stake in shares of Becton, Dickinson and Company by 8.5% during the 2nd quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock valued at $2,269,960,000 after buying an additional 1,177,256 shares during the last quarter. First Eagle Investment Management LLC boosted its stake in shares of Becton, Dickinson and Company by 15.8% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after buying an additional 1,887,224 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of Becton, Dickinson and Company during the 2nd quarter valued at approximately $474,993,000. Finally, Legal & General Group Plc grew its position in shares of Becton, Dickinson and Company by 1.5% during the second quarter. Legal & General Group Plc now owns 2,101,695 shares of the medical instruments supplier’s stock worth $318,050,000 after buying an additional 30,766 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael Feld sold 165 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,906 shares of company stock worth $1,265,855 over the last ninety days. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $200.21 on Friday. The stock has a market capitalization of $55.16 billion, a PE ratio of 14.95, a price-to-earnings-growth ratio of 13.10 and a beta of 0.21. The business’s fifty day moving average price is $185.10 and its 200 day moving average price is $164.86. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $200.47.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. Royal Bank Of Canada increased their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Jefferies Financial Group reissued a “buy” rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Barclays began coverage on shares of Becton, Dickinson and Company in a research report on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 target price for the company. Finally, UBS Group assumed coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus price target of $185.07.

Check Out Our Latest Analysis on Becton, Dickinson and Company

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.